Paramount Resources is decently profitable with natural gas prices at a cyclical bottom. The stock's current low price-earnings ratio signals a contrarian opportunity. Despite a temporary drop in free cash flow, Paramount's low debt enables it to wait for a natural gas price recovery.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
PARA's third-quarter performance is expected to have been aided by the company's expanding clientele and growing streaming services amid persisting inflation.
David Ellison, Larry Ellison's son, is set to take over Paramount. Not David Zaslav, the CEO of Warner Bros.
Paramount Global (PARAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Paramount Global-B (PARA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Paramount Group, Inc. (NYSE:PGRE ) Q3 2024 Earnings Call October 31, 2024 10:00 AM ET Company Participants Tom Hennessy - Vice President, Business Development and Investor Relations Albert Behler - Chairman, Chief Executive Officer and President Wilbur Paes - Chief Operating Officer, Chief Financial Officer and Treasurer Peter Brindley - Executive Vice President and Head, Real Estate Conference Call Participants Blaine Heck - Wells Fargo Stephen Sakwa - Evercore ISI Dylan Burzinski - Green Street Operator Good day, ladies and gentlemen. Thank you for standing by.
An amended FCC filing by Skydance today says that David Ellison will hold 100% of the Ellison family's interest in Paramount once that deal closes. The clarification is an attempt to allay concern that control will reside with his father, Oracle co-founder and CEO, Larry Ellison.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Investors need to pay close attention to Paramount Global (PARAA) stock based on the movements in the options market lately.
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Paramount Global (PARAA) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated metastatic colorectal cancer, potentially opening a massive market with an estimated $567 million to $3.78 billion in annual US sales. Onvansertib has demonstrated superior efficacy and safety over historical controls and competitors, particularly in bevacizumab-naïve patients, with impressive objective response rates and progression-free survival. Positive data from the ongoing CRDF-004 trial could lead to significant upside for Cardiff, attracting potential partnerships or acquisition interest from big pharma, including Pfizer.